ADK1 Antibody

What is ADK1a antibody and what epitopes does it recognize?

ADK1a is a mouse monoclonal antibody that specifically recognizes conformational epitopes on intact adeno-associated virus (AAV) capsids. According to structural studies, ADK1a binds to the 3-fold protrusion of the AAV1 capsid . The antibody recognizes assembled capsids only, not denatured capsid proteins or unassembled capsid proteins . The binding sites involve multiple amino acid residues that come into proximity only in the correctly assembled capsid structure. These residues include those in the variable regions (VR) that are involved in AAV1 transduction .

What are the cross-reactivity profiles of ADK1a antibody?

ADK1a exhibits defined cross-reactivity across AAV serotypes:

• Reactive with: AAV1, AAV6, AAV12 intact capsids

• No reactivity with: AAV2, AAV3, AAV4, AAV5, AAV7, AAV8, AAV9, AAV11, AAVDJ, AAVrh10, AAVrh74

This selective cross-reactivity profile makes ADK1a valuable for distinguishing between specific AAV serotypes in research applications.

What is the difference between mouse monoclonal ADK1a and human chimeric ADK1a-h1?

The human chimeric antibody ADK1a-h1 is derived from the mouse monoclonal ADK1a antibody. It combines the mouse antigen-binding region with a human Fc region . While both antibodies recognize the same epitopes, they differ in:

• Binding affinity: Mouse ADK1a has a KD value for AAV1 of <1.0E-12 M, while human chimeric ADK1a-h1 has a KD value of 8.8E-12 M

• Applications: Human chimeric ADK1a-h1 is specifically suitable for dot blot, neutralization assay, and serology ELISA , while mouse ADK1a has additional applications in ICC/IF

• Immunogenicity: The human chimeric version potentially offers reduced immunogenicity in human applications compared to the mouse monoclonal antibody

How should I design neutralization assays using ADK1a antibody?

For optimal neutralization assay design with ADK1a antibody:

• Pre-incubation protocol: Pre-incubate ADK1a with AAV viral particles (e.g., AAV1-NanoLuc® or AAV6-NanoLuc®) for 30 minutes at room temperature with shaking at 300 rpm using antibody concentrations ranging from 0.2-3,000 ng/ml

• Cell preparation: Plate HEK293 cells at a concentration of 200,000 cells/ml in DMEM supplemented with 1% FCS (100 μl per well)

• Infection procedure: Add 20 μl of the virus-antibody mixture to cells and incubate for 16-24 hours at 37°C

• Detection method: Add Extracellular NanoLuc Inhibitor and Nano-Glo® Live Cell Assay System (Promega), incubate for 5 minutes at room temperature with shaking at 300 rpm

• Measurement and analysis: Measure luminescence using an appropriate reader and plot the data to determine EC50 values

The expected EC50 values for ADK1a are approximately 2 ng/ml for both AAV1 and AAV6 neutralization, though this is assay-dependent .

What methods are recommended for determining binding affinity of ADK1a to different AAV serotypes?

Biolayer interferometry (BLI) analysis is the recommended method for determining the binding affinity of ADK1a to different AAV serotypes, as demonstrated in comparative studies . This approach allows for:

• Quantitative measurement: Determines precise KD values that indicate binding strength

• Comparative analysis: Facilitates direct comparison between different antibody formats (e.g., mouse monoclonal vs. human chimeric)

• Serotype specificity: Enables evaluation across multiple AAV serotypes to establish cross-reactivity profiles

The table below summarizes binding affinity data obtained through BLI analysis:

Note: Lower KD values indicate higher binding affinity, with the detection limit being 1.0E-12 M .

How can I differentiate between full and empty AAV capsids using ADK1a antibody?

ADK1a antibody can be effectively utilized to differentiate between full and empty AAV capsids through several techniques:

• Dot blot analysis: Apply native (non-denatured) AAV capsids to nitrocellulose membrane, block with 5% milk in PBST, then probe with ADK1a at 100 ng/ml followed by appropriate HRP-conjugated secondary antibody . This method detects intact capsids regardless of genome content.

• ELISA-based quantitation: ADK1a can be used as both capture and detection antibody in sandwich ELISA formats specifically developed for quantitation of AAV1 capsids . This approach allows for determination of total capsid concentration.

• Combined with density gradient separation: When used in conjunction with iodixanol gradient separation (which physically separates full and empty capsids based on density), ADK1a can confirm the identity and integrity of the separated fractions .

• Comparative analysis with genome-specific detection: By comparing the signal from ADK1a (which detects all intact capsids) with genome-specific detection methods (such as qPCR), researchers can calculate the ratio of full to empty capsids in a preparation .

What are common issues when using ADK1a antibody for dot blot analysis and how can they be resolved?

Common issues and their solutions include:

• High background signal:

  • Problem: Non-specific binding to membrane

  • Solution: Increase blocking time from 45 minutes to 1-2 hours using 5% milk in PBST; reduce antibody concentration; add 0.1-0.5% BSA to antibody dilution buffer

• Weak or no signal with denatured samples:

  • Problem: ADK1a recognizes conformational epitopes only

  • Solution: Use only non-denatured samples; ADK1a cannot be used for detection of denatured capsid proteins

• Cross-reactivity issues:

  • Problem: Unexpected reactivity with other AAV serotypes

  • Solution: Include appropriate positive and negative controls for each serotype; verify specificity using side-by-side comparison with known reactive (AAV1, AAV6) and non-reactive (AAV2, AAV5, etc.) serotypes

• Optimizing detection sensitivity:

  • Problem: Insufficient signal strength

  • Solution: Extend primary antibody incubation time from 1.5 hours to overnight at 4°C; use more sensitive chemiluminescent substrates such as Pierce™ ECL Plus instead of standard ECL

How should storage and reconstitution of ADK1a antibody be managed to maintain optimal activity?

For optimal storage and reconstitution of ADK1a antibody:

• Before reconstitution:

  • Store lyophilized antibody at 2-8°C until the indicated expiry date

  • Avoid exposure to moisture and keep vial tightly sealed

• Reconstitution process:

  • Reconstitute in 1 ml distilled water to achieve final concentration of 50 μg/ml

  • The reconstituted solution will contain 0.09% sodium azide, 0.5% BSA in PBS buffer, pH 7.4

  • Allow complete dissolution by gentle inversion rather than vortexing

• After reconstitution:

  • Short-term storage (up to 3 months): 2-8°C

  • Long-term storage: Make aliquots and store at -20°C

  • Avoid repeated freeze/thaw cycles as they may compromise antibody activity

• Working solution preparation:

  • Dilute to working concentration only immediately before use

  • Use high-quality, protein-free buffer for dilutions

  • For most applications, BSA-containing buffers are recommended to stabilize the antibody

How effective is ADK1a antibody for neutralizing AAV vectors in pre-clinical gene therapy research?

ADK1a demonstrates potent neutralization activity against AAV1 and AAV6 vectors, making it valuable for pre-clinical gene therapy research:

• Neutralization potency: ADK1a shows EC50 values of approximately 2 ng/ml for both AAV1 and AAV6 neutralization , indicating high neutralization efficiency at low concentrations.

• Mechanism of action: ADK1a binds to conformational epitopes on the 3-fold protrusion of the AAV capsid , potentially interfering with receptor binding or cellular entry mechanisms essential for transduction.

• Applications in gene therapy research:

  • Antibody-mediated neutralization models: ADK1a can be used to simulate the effects of pre-existing neutralizing antibodies in gene therapy recipients

  • Epitope mapping: The well-characterized binding sites of ADK1a contribute to understanding neutralization-sensitive regions on AAV capsids

  • Vector engineering: Data from ADK1a neutralization studies informs the development of capsid modifications to escape antibody neutralization

• Comparative analysis: When used alongside its human chimeric counterpart (ADK1a-h1), researchers can evaluate whether humanization affects neutralization properties, providing insights into potential clinical translation .

What is the significance of ADK1a epitope location for designing AAV vectors with reduced immunogenicity?

The epitope location of ADK1a on the AAV1 capsid has significant implications for designing AAV vectors with reduced immunogenicity:

• Structural insights: The ADK1a epitope has been mapped to the 3-fold protrusion of the AAV1 capsid , a region known to be immunologically prominent and involved in receptor binding.

• Functional considerations: Multiple contact sites and footprint residues have been identified for ADK1a binding, including residues that are involved in AAV1 transduction . This indicates a potential overlap between immunogenic regions and functionally important domains.

• Rational design strategies:

  • Targeted mutations: Modifying specific amino acids within the ADK1a epitope may reduce antibody binding while preserving transduction efficiency

  • Epitope masking: Adding shielding moieties (such as PEG or glycans) near the ADK1a binding site can reduce antibody accessibility

  • Serotype chimeras: Creating hybrid vectors that incorporate structural elements from AAV serotypes not recognized by ADK1a (e.g., AAV2, AAV5, AAV8)

• Translation to clinical applications: Understanding the ADK1a epitope contributes to the development of AAV vectors that can evade neutralization by pre-existing antibodies, which are present in 30-60% of individuals depending on serotype and geographical location .

How does the binding affinity of ADK1a compare with other anti-AAV antibodies for different serotypes?

The binding affinity of ADK1a compared to other anti-AAV antibodies shows distinctive patterns across serotypes:

• ADK1a versus other anti-AAV1 antibodies:

  • ADK1a shows exceptionally high affinity for AAV1 (KD <1.0E-12 M)

  • This compares favorably to other anti-AAV1 antibodies like 4E4 and 5H7, indicating ADK1a may recognize a particularly stable epitope

• Cross-serotype comparison:

  • ADK1a has high affinity for both AAV1 and AAV6 (KD <1.0E-12 M for both)

  • In contrast, antibodies like A20 show varying affinities across serotypes: AAV2 (KD 2.6E-11 M), AAV3 (KD <1.0E-12 M)

  • ADK5a and ADK5b (anti-AAV5 antibodies) show moderate affinities (KD ~5-6E-11 M)

• Impact of chimeric modifications:

  • Humanization of ADK1a to create ADK1a-h1 slightly reduces binding affinity for AAV1 (from KD <1.0E-12 M to 8.8E-12 M)

  • Similarly, humanization of ADK8 to ADK8-h1 maintains high affinity (KD <1.0E-12 M for both)

  • This pattern suggests that framework modifications can be made without dramatic loss of binding properties

The comprehensive affinity data across multiple antibodies and serotypes provides valuable benchmarks for researchers developing new anti-AAV detection or neutralizing reagents.

How can ADK1a antibody be used in combination with artificial intelligence approaches for antibody engineering?

The integration of ADK1a antibody information with artificial intelligence (AI) approaches represents an emerging frontier in antibody engineering:

• Epitope-driven design: The well-characterized epitope of ADK1a can serve as a template for AI-based de novo antibody design, as demonstrated in recent target-agnostic, epitope-driven approaches . Researchers could:

  • Use the ADK1a binding footprint to inform computational models for designing new anti-AAV antibodies

  • Apply structural information from ADK1a-AAV complexes to train AI models for predicting antibody-antigen interactions

• Optimization through machine learning:

  • Sequence-structure-function relationships from ADK1a can inform machine learning algorithms to predict modifications that enhance specificity or affinity

  • By analyzing the differences between mouse ADK1a and human chimeric ADK1a-h1, AI models can better understand the impact of framework modifications on binding properties

• Scaling antibody production and screening:

  • AI approaches can rapidly screen virtual libraries of ADK1a variants to identify candidates with improved properties

  • As demonstrated in recent research, AI methods can successfully scale from thousands to trillions of possible antibody combinations, identifying high-affinity binders with specific properties

• Reducing immunogenicity:

  • Machine learning models trained on antibody immunogenicity data can help predict and minimize potential immunogenic regions in antibodies like ADK1a

  • This is particularly relevant for therapeutic applications or long-term research use of these antibodies

What are the considerations for using ADK1a in developing neutralization assays for novel AAV variants?

When developing neutralization assays for novel AAV variants using ADK1a, researchers should consider:

• Cross-reactivity assessment:

  • Novel AAV variants, especially those engineered from AAV1 or AAV6 backbones, may retain ADK1a binding sites

  • Preliminary screening should determine if ADK1a recognizes the novel variant before developing a neutralization assay

  • A dot blot analysis using native capsids (1E+09-1E+10 capsids) can quickly establish recognition

• Reporter system selection:

  • The established protocol using NanoLuc® viral particles offers high sensitivity

  • For novel variants, consider:

    • Adapting the reporter gene to match the packaging capacity of the variant

    • Ensuring the promoter is active in the chosen cell line

    • Verifying that the novel variant can efficiently transduce the cell line used in the assay

• Assay standardization:

  • Include wild-type AAV1 or AAV6 as reference controls alongside the novel variant

  • Establish a standard curve for each variant to account for potential differences in transduction efficiency

  • Normalize EC50 values relative to the reference serotype to enable meaningful comparisons

• Interpretation challenges:

  • A shift in neutralization profile could indicate:

    • Altered epitope presentation on the novel variant

    • Changed capsid stability affecting antibody accessibility

    • Modified cellular entry mechanisms that may bypass certain neutralization steps

  • Complementary structural studies (e.g., cryo-EM) may be needed to fully interpret unexpected neutralization results

• Prevalence of pre-existing immunity:

  • Novel AAV variants may be designed to escape natural pre-existing immunity

  • ADK1a neutralization assays can serve as a benchmark to compare neutralization susceptibility between standard and novel variants

What is known about the relationship between adenylate kinase (ADK1/AK1) antibodies and the monoclonal antibodies against AAV1 (ADK1a)?

It is important to clarify that despite similar nomenclature, ADK1/AK1 (adenylate kinase) antibodies and ADK1a (anti-AAV1) monoclonal antibodies represent distinct research tools targeting completely different molecules:

• Biological targets:

  • ADK1/AK1 antibodies: Target the adenylate kinase enzyme, a 22kDa protein involved in cellular energy metabolism and phosphate group transfer between adenine nucleotides

  • ADK1a antibody: Recognizes conformational epitopes on adeno-associated virus serotype 1 (AAV1) capsids

• Research applications:

  • ADK1/AK1 antibodies: Used to study cellular energy balance, metabolic pathways, and potentially metabolic disorders

  • ADK1a antibody: Applied in AAV vector characterization, neutralization studies, and gene therapy research

• Structural considerations:

  • ADK1/AK1: The antibody recognizes a sequence corresponding to amino acids 1-194 of human AK1 protein (NP_000467.1)

  • ADK1a: Binds to conformational epitopes formed by multiple amino acid residues that come together only in the properly assembled AAV1 capsid

• Experimental contexts:

  • Research involving ADK1/AK1 often focuses on ATP metabolism, such as the role of Adk1p in pre-replicative complex assembly in yeast

  • ADK1a research typically centers on viral vector characterization, neutralization, and immunogenicity in gene therapy contexts

Researchers should be careful to clearly specify which entity they are referring to when using these abbreviations to avoid confusion in the literature.

What are the optimal conditions for using ADK1a antibody in immunocytochemistry/immunofluorescence applications?

For optimal results when using ADK1a antibody in immunocytochemistry (ICC) and immunofluorescence (IF) applications:

• Sample preparation:

  • Fix cells with 4% paraformaldehyde for 15-20 minutes at room temperature

  • For intracellular detection of AAV capsids, permeabilize with 0.1-0.2% Triton X-100 in PBS for 10 minutes

  • Blocking should be performed with 5% normal serum (from the same species as the secondary antibody) and 0.3% Triton X-100 in PBS for 1 hour

• Antibody dilution and incubation:

  • Use ADK1a at a 1:20 dilution (2.5 μg/ml final concentration)

  • Incubate with primary antibody overnight at 4°C for optimal sensitivity and specificity

  • Use secondary antibody (anti-mouse IgG) conjugated to appropriate fluorophore at manufacturer's recommended dilution

• Controls and validation:

  • Include cells infected with AAV1 as positive control

  • Use cells infected with non-reactive AAV serotypes (e.g., AAV2, AAV5) as negative controls

  • For dual labeling experiments, include appropriate single-label controls to assess channel crosstalk

• Detection optimization:

  • ADK1a detects intact capsids, making it ideal for tracking virus internalization and trafficking

  • For co-localization studies, combine with antibodies against cellular compartment markers (endosomes, lysosomes, etc.)

  • Signal amplification systems may be used for detecting low levels of AAV capsids, but background controls become more critical

• Imaging considerations:

  • Confocal microscopy is recommended for precise localization of AAV capsids

  • When quantifying signals, establish consistent exposure settings based on positive controls

  • Z-stack imaging may be necessary to fully capture the distribution of internalized AAV particles

How can I develop a quantitative ELISA using ADK1a for measuring AAV1 capsid concentration?

To develop a quantitative ELISA using ADK1a for measuring AAV1 capsid concentration:

• Plate preparation:

  • Coat high-binding ELISA plates with ADK1a at 1-2 μg/ml in carbonate-bicarbonate buffer (pH 9.6) overnight at 4°C

  • Wash plates 3-5 times with PBST (PBS + 0.1% Tween-20)

  • Block with 5% non-fat dry milk in PBST for 1-2 hours at room temperature

• Standard curve preparation:

  • Use purified, empty AAV1 capsids as standards

  • Prepare a dilution series ranging from 1E+07 to 1E+10 capsids/well

  • Include blank controls (buffer only) for background subtraction

• Sample processing:

  • Dilute unknown samples to fall within the standard curve range

  • For crude samples, consider pre-clearing cellular debris by centrifugation

  • If detecting AAV in complex biological matrices (serum, tissue lysates), optimize sample dilutions to minimize matrix effects

• Detection system:

  • Two approaches are possible:

    • Sandwich ELISA: Use biotinylated ADK1a as detection antibody, followed by streptavidin-HRP

    • Direct detection: Use a different anti-AAV1 antibody that recognizes a non-competing epitope, followed by appropriate HRP-conjugated secondary antibody

  • Develop with TMB substrate and stop with 2N H2SO4

  • Read absorbance at 450 nm (with 620 nm reference wavelength)

• Data analysis and validation:

  • Generate a standard curve using 4-parameter logistic regression

  • Calculate capsid concentrations in unknown samples based on the standard curve

  • Validate the assay by:

    • Determining limit of detection and quantification

    • Assessing intra- and inter-assay variability (should be <15%)

    • Confirming linearity of dilution for representative samples

    • Testing specificity with other AAV serotypes (should show no reactivity with AAV2, AAV5, etc.)

The detection range for this ELISA can typically span 3-4 orders of magnitude, with sensitivity down to approximately 1E+07 capsids/well.